Objective: To review the management of primary hyperparathyroidism in pregnant women by focusing on the use of preoperative localization procedures and minimally invasive parathyroid surgery during pregnancy.
Introduction
Primary hyperparathyroidism is a common disorder for which surgery remains the definitive treatment for patients with significant elevations of the serum calcium or complications of the disease. For those with mild, asymptomatic disease surgery can be avoided unless the degree of hypercalcemia becomes more severe or complications arise. [1] [2] [3] The management of asymptomatic individuals with primary hyperparathyroidism depends on the degree of elevation of the serum calcium and the presence or absence of renal and bone disease. Recently revised guidelines have been published by the Third International Workshop to assist clinicians with decisions regarding surgery for patients with hyperparathyroidism. 3 These guidelines do not include any recommendations for pregnant women.
Primary hyperparathyroidism is rarely diagnosed during pregnancy. Since the first reported case in 1931, 4 approximately 150 patients have been reported in the English medical literature. Although calcium levels as high as 25.8 mg 100 ml À1 have been reported during pregnancy, 5 most patients have more modest degrees of hypercalcemia. Clearly, any decision regarding surgery for a pregnant woman with primary hyperparathyroidism is more complex than in men or non-pregnant women. On account of the rarity of primary hyperparathyroidism in young pregnant women, no evidence-based guidelines exist to assist clinicians regarding the management of primary hyperparathyroidism during pregnancy.
When surgery is deemed necessary during pregnancy, the second trimester is generally considered to be the optimal time. Preoperative localization of parathyroid adenomas remains challenging in patients who need to undergo surgery during pregnancy. Imaging studies using ionizing radiation, such as sestamibi scans, must be avoided. Although ultrasound of the neck is safe to use during pregnancy, the results are operator-dependent with low sensitivity in localizing parathyroid adenomas preoperatively. 6 We report two cases of severe, symptomatic primary hyperparathyroidism that were cured surgically during pregnancy and also review the medical literature. We believe that one of our cases is the first reported instance in which there was successful preoperative localization of a parathyroid adenoma by aspiration for measurement of a parathyroid hormone (PTH) level during pregnancy.
Patients and materials
This study was approved by the Louisiana State University Health Sciences Center Institutional Review Board for Human Research Subjects. The data reported were accessed from their medical records and informed consent was obtained from the patients for all treatments and procedures.
Patients had ultrasounds of the thyroid gland and the area posterior to the thyroid carried out with a GE LogiQ 9 system using a 7.5-MHz probe. Nodules suspected of being parathyroid adenomas were aspirated with 25-G needles. The needles and syringes were washed out with 1 cc of 0.9% saline and the samples placed into sterile tubes. The samples were assayed for PTH using an Immulite Turbo 1000 Intact PTH immunoassay system. This assay is a solidphase, chemiluminescent immunometric assay for the quantitative determination of intact PTH. The assay is designed to measure PTH in serum or plasma with an analytical sensitivity of 4 pg ml À1 and a reference range of 8.0-74 pg ml À1 . The intra-assay coefficient of variation is 6.7% at a concentration of 49 pg ml À1 and 6.5% at a concentration of 247 pg ml À1 . 25-hydroxyvitamin D was measured by an immunochemiluminometric assay carried out on the DiaSorin Liason Instrument (LabCorp) with a reference range of 32-100 ng ml À1 . 1,25-dihydroxyvitamin D was measured by LabCorp by column chromatography followed by radioimmunoassay with a reference range of 15.9-55.6 pg ml À1 . Routine chemistry tests were carried out using an Abbott Architect instrument.
Case 1
A 30-year-old gravida 2, para 1 woman was diagnosed with hypercalcemia on routine prenatal testing done at 8.5-weeks gestation. Her first child was delivered by C-section outside the United States and records were unavailable. Serum calcium levels, corrected for the serum albumin concentration ranged from 13.5-14 mg 100 ml À1 (8.9-10.0 mg 100 ml À1 ). She had symptoms of diffuse bone pain, myalgias and nausea, as well as a past history of nephrolithiasis. She had no history of fractures. She could not recall any family history of calcium disorders, pituitary tumors or peptic ulcer disease. Pertinent laboratory tests included an intact PTH level of 122 pg ml À1 (8.0-74 pg ml À1 ), 25-hydroxyvitamin D 7.6 ng ml À1 (32-100 ng ml À1 ), 1,25-dihydroxyvitamin D 47.9 pg ml À1 (15.9-55.6 pg ml À1 ) phosphorus 2.4 mg 100 ml À1 (2.3-4.7 mg 100 ml À1 ), and 24 h urine calcium excretion of 445 mg.
Intravenous 0.9% NaCl was infused with only limited success in lowering her serum calcium level. In view of her severe hypercalcemia resistant to medical therapy, and potential maternal and fetal complications, surgical management was deemed necessary.
Localizing procedures were attempted to try and identify a parathyroid adenoma in hopes of carrying out a minimally invasive parathyroid surgery. A magnetic resonance imaging (MRI) without gadolinium identified a 15 mm hyperintense lesion in the right lobe of the thyroid on T2 weighted images. Abnormalities were not noted in the left lobe. An ultrasound of the neck identified two areas that could have represented parathyroid adenomas, a left 1.1 Â 0.8 Â 1.0 cm intrathyroidal hypoechoic nodule (Figures 1a  and b ) and a right inferior intrathyroidal hypoechoic nodule measuring 1.1 Â 0.8 Â 1.1 cm (Figures 1c and d) . Both lesions were aspirated under ultrasound guidance using 25-G needles and sent for cytology. In addition, the needle was washed out with 1 cc of 0.9% saline and sent for the measurement of PTH. The PTH level from the left-sided lesion was >2500 pg ml À1 , whereas the level from the right side was <5 pg ml À1 . The cytologies from both nodules showed epithelial cells, but the cytopathologist was unable to distinguish whether these cells were of thyroid or parathyroid origin ( Figure 2 ). After supplementation with ergocalciferol a minimally invasive parathyroidectomy was carried out at 11-weeks gestation. A 1.1 Â 0.85 Â 0.5 cm left intrathyroidal parathyroid gland weighing 200 mg was removed through a 2 cm incision. The intraoperative PTH decreased from 197 to <3 pg ml À1 . Postoperatively her symptoms of bone pain, fatigue and myalgias improved significantly and no postoperative hypocalcemia was noted. Six weeks after surgery her corrected serum calcium was 9.5 mg 100 ml À1 with a PTH of 19.8 pg ml À1 . She remained normocalcemic throughout the remainder of her pregnancy without hypertension or proteinuria. Fetal ultrasounds showed a single intrauterine pregnancy with appropriate fetal growth and normal amniotic fluid. At 38 weeks an elective C-section under spinal anesthesia was carried out because of her history of a previous C-section. She delivered a viable, healthy female with Apgar scores of 8 at 1 min and 9 at 5 min without an evidence of neonatal hypocalcemia or tetany.
Case 2
A 22-year-old African-American woman, gravida 2, para 1 was found to be hypercalcemic during her first visit to the obstetrical clinic at 21-weeks gestation. Nine months earlier she had an intrauterine fetal death at 32-weeks gestation with her first pregnancy. At that time she was noted to have hypercalcemia with a serum calcium level of 12.3 mg 100 ml À1 , but failed to return for a follow up. The patient was admitted to the high-risk obstetrical service with serum calcium levels, corrected for albumin, between 12 and 13 mg 100 ml À1 . Intravenous hydration with 0.9% saline was started. She was asymptomatic without any history of nephrolithiasis, fractures, peptic ulcer disease, myalgias or diffuse bone pain. There was no known family history of hypercalcemia, peptic ulcer disease or endocrine tumors. Her intact PTH level was 114 pg ml À1 , 25-hydroxyvitamin D 11.1 ng ml À1 , 1,25-dihydroxyvitamin D 144.5 pg ml À1 and phosphorus 2.4 mg 100 ml À1 . Her urinary calcium excretion was high with a value of 576 mg every 24 h. In view of the patient's previous history of fetal loss, as well as the severe degree of hypercalcemia, localization procedures were ordered and surgery planned. Both an ultrasound and magnetic resonance imaging of the neck failed to reveal any lesion that was suspicious for a parathyroid adenoma. At 22-weeks gestation the patient underwent parathyroid surgery. Both sides of the neck were explored with excision of a left lower parathyroid adenoma. The intraoperative PTH decreased from 215 to 28.9 pg ml
À1
. Pathological examination of the resected tissue confirmed a 1.4 Â 1.2 Â 0.6 cm parathyroid adenoma weighing 310 mg. Her postoperative course was uncomplicated without either hypocalcemia or hypercalcemia. Six weeks after surgery she had a normal serum calcium level of 9.4 mg 100 ml À1 with a PTH of 47 pg ml À1 . She remained normocalcemic throughout the remainder of her pregnancy without hypertension or proteinuria. Fetal ultrasounds carried out at appropriate intervals were consistent with a single intrauterine pregnancy with appropriate fetal growth and normal amniotic fluid. At 39 weeks the patient had an uncomplicated vaginal delivery under epidural analgesia. A healthy, viable male was born with Apgar scores of 7 at 1 min and 8 at 5 min without any neonatal hypocalcemia or tetany.
Discussion
Primary hyperparathyroidism is a common disorder most often diagnosed after 40s. In non-pregnant individuals, the most common cause of primary hyperparathyroidism is a solitary parathyroid adenoma, accounting for 80-85% of the cases.
The remaining 15-20% are attributed to diffuse hyperplasia (10-12%), double or triple adenomas (2%) or carcinomas (1%). 3 However, given the relatively young age of pregnant women, when Parathyroid surgery in pregnancy P Pothiwala and SN Levine hyperplasia is found, the possibility of a familial syndrome, such as multiple endocrine neoplasia type 1, should be considered. As pregnancy alone affects the metabolism of calcium and phosphorus, and maternal calcium disorders can significantly affect fetal bone mineralization, 7 primary hyperparathyroidism concurrent with pregnancy may present with several unique features. In normal pregnancy there is an active transport of 25-30 g of calcium to the fetus, primarily mediated by PTH-related peptide produced by the placenta. 8 1,25-dihydroxyvitamin D levels are increased during normal pregnancy due to PTH independent placental 1-alpha hydroxylase activity along with PTH dependant synthesis of this active vitamin D metabolite in the kidneys. 9 As a result, in normal pregnancy the intestinal absorption of calcium is increased resulting in a state of absorptive hypercalciuria. Serum levels of PTH are low in the first half of pregnancy and increased towards the end of pregnancy. 10 There is an increase in the extracellular fluid volume, and a decrease in the concentration of serum albumin during pregnancy. Thus, total serum calcium is low in pregnancy, but ionized calcium is normal. Some of these changes may mask the degree of hypercalcemia that might, otherwise, be more apparent in non-pregnant women. Finding an increased total or ionized calcium with a clearly elevated PTH, or one that is in the high-normal range, would be highly suspicious for the diagnosis of primary hyperparathyroidism during pregnancy.
Precise data concerning the complications of primary hyperparathyroidism during pregnancy are limited. In one review maternal complication rates as high as 67% were reported.
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Complications include nephrolithiasis, pancreatitis, hyperemesis gravidarum, the HELLP syndrome and pre-eclampsia, and in severe cases, a hypercalcemic crisis with nausea, vomiting, mental status changes, dehydration, uremia and coma. 11, 12 Although documented in isolated case reports, an increased risk of fractures because of hyperparathyroidism during pregnancy is rare given the young age of the affected individuals. 13, 14 Maternal hypercalcemia increases the risk of perinatal complications, primarily neonatal hypocalcemia and tetany. Perinatal mortality up to 25% has been observed. 15 Chronic maternal hypercalcemia leads to high calcium levels in the fetal circulation. This, in turn, suppresses the fetal parathyroid glands leading to decreased PTH secretion, which may persist even after delivery, thus causing neonatal hypocalcemia. Although most cases of neonatal hypocalcemia are transient, a more sustained hypocalcaemia has been reported. 16 Other factors that could contribute to neonatal hypocalcaemia, include hypomagnesemia, elevated calcitonin levels (from intrauterine hypercalcemia), prematurity and the high phosphate content of infant formula. 17, 18 The role of medical management of primary hyperparathyroidism diagnosed during pregnancy is mostly supportive with vigilant obstetrical care. Adequate hydration has been a primary therapy for treating asymptomatic, mild disease.
Use of pharmacological agents has been limited to more severe cases, either before surgery or during the third trimester when surgery is potentially of greater risk. Intravenous bisphosphonates commonly prescribed to lower the serum calcium are contraindicated in pregnancy because of their effects on fetal skeletal development. Subcutaneous calcitonin and oral phosphates are both Food and Drug Administration (FDA) class C for use in pregnancy. The administration of calcitonin is limited by tachyphylaxis and oral phosphates with concerns of soft tissue calcifications and diarrhea. In a single case report, high doses of intravenous magnesium were used for hypercalcemia and premature labor in the third trimester and was found to decrease calcium by lowering PTH levels. 19 If chosen, medical therapy should include serial monitoring of fetal ultrasounds and frequent obstetrical visits, as these women are at high risk for premature labor and eclampsia.
In 1947 Petit and Clark carried out the first parathyroidectomy during pregnancy. 20 Subsequent case reports have shown that parathyroidectomy carried out during pregnancy for primary hyperparathyroidism reduces the risk of fetal and maternal morbidities. In a retrospective analysis of 109 cases reported of primary hyperparathyroidism from 1930 to 1990, 70 patients were treated medically, whereas 39 patients had surgery during pregnancy. 21 Among patients, those who were treated medically, 53% of neonates had complications and 16% died. In contrast, in the group managed surgically, 12.5% of neonates had a complication and only 2.5% died. The optimal time for surgery has generally been considered the second trimester, while management of newly recognized clinically significant hypercalcemia in the third trimester is under debate. In 2005 Schnatz et al. reviewed 16 patients with primary hyperparathyroidism who were treated surgically after 27 weeks of gestation. Forty-two percent of fetuses and 68.7% of mothers had postoperative complications as a direct result of the surgery. Reported complications included renal failure, premature rupture of membranes, pre-eclampsia and postoperative hypocalcemia. 22 The decision to proceed with surgery during the third trimester must be individualized based on the degree of hypercalcemia, fetal maturity and obstetrical history. 23 If surgery for maternal hyperparathyroidism is deemed necessary then preoperative localization of an adenoma during pregnancy remains challenging. Radioactive isotope scans using sestamibi must be avoided secondary to concerns related to radiation exposure of the fetus. Ultrasound can be used safely during pregnancy; however, the results are highly operatordependent with the sensitivity in localizing a parathyroid adenoma reported to be only 50-60%. 6 Ultrasound-guided aspiration of a lesion which is suspicious for a parathyroid adenoma with the measurement of PTH has been described in non-pregnant individuals. In 1983 Doppman et al. described computedtomography-guided aspiration of neck masses for measurement of PTH. PTH levels were much higher when aspirated from parathyroid adenomas compared with aspirates from the sternocleidomastoid muscle or thyroid gland. 24 Subsequently, results of two prospective studies measuring PTH from needle washouts obtained by aspiration of neck lesions of non-pregnant individuals were reported. There was excellent specificity (95-100%) and sensitivity (91-100%) in identifying parathyroid adenomas when compared with thyroid aspirates obtained from normocalcemic or hypercalcemic individuals. 25, 26 One of our patients had a PTH level of >2500 pg ml À1 from the surgically confirmed parathyroid adenoma and <5 pg ml À1 from the thyroid nodule which is consistent with data in non-pregnant individuals. We could find no controlled trial or other data concerning PTH levels from needle aspirates of neck lesions in either hypercalcemic or eucalcemic pregnant women. Cytological examination is generally done along with measurement of PTH from the needle washout, however, differentiating parathyroid from thyroid epithelial cells remains difficult. 27 Recently, multispectral image analysis using both spatial and spectral image with a neural network-based artificial intelligence system has been shown to differentiate follicular cells from parathyroid cells with 98% specificity. 28 Fine-needle aspiration of a suspected parathyroid lesion under ultrasound guidance is generally considered a very safe procedure in experienced hands. Reported complications are few and generally limited to local hemorrhage or swelling. There has been one report of increased fibrosis after needle aspiration of parathyroid adenomas resulting in subsequent surgical difficulties. 29 Fibrosis or adverse pathological findings have not been reported from other centers. 25, 26 One of our patients underwent a successful fine-needle aspiration without any noticeable fibrosis in the surgical specimen or technical difficulties during surgery. Another concern regarding fine-needle aspiration of a suspected parathyroid lesion is the implantation of malignant cell along the needle track if the patient were to have a parathyroid carcinoma. 30 Although parathyroid cancer is rare, we recommend caution against routine use of needle aspiration of suspected parathyroid lesions especially in non-pregnant individuals where other localization modalities are available, particularly if the clinical suspicion of a parathyroid carcinoma is high.
Minimally invasive parathyroidectomy, limiting the operative field to the region where an adenoma has been localized has been shown to be as effective as bilateral neck dissection in prospective trials and is associated with shorter hospital stay, smaller scars and better short term patient satisfaction. 31, 32 Since 1993, use of intraoperative PTH monitoring has been used extensively and is particularly helpful in patients with discordant localization studies. 33 There are no published reports concerning minimally invasive parathyroidectomy or bilateral neck exploration with use the of intraoperative PTH monitoring to confirm the removal of an adenoma in pregnant women. In one of our patients, two intrathyroidal lesions were seen on a preoperative ultrasound of the neck. By using ultrasound-guided fine-needle aspiration of both lesions with the measurement of PTH we were able to localize the adenoma, thereby allowing our patient to undergo a minimally invasive parathyroidectomy. Successful surgery was confirmed when the intraoperative PTH level decreased from 197 to <3 pg ml À1 . In our second case the adenoma could not be localized with imaging procedures. A bilateral neck exploration was done with the removal of a parathyroid adenoma and decrease of the intraoperative PTH from 215 to 28.9 pg ml À1 . Intraoperative g probe was not used in either patient because of the concern of fetal radiation exposure.
Parathyroidectomy in experienced hands is an extremely safe procedure even during pregnancy. Recently, a retrospective series of 77 pregnancies in 32 women with primary hyperparathyroidism was reported, 15 of whom had a parathyroidectomy during the second trimester. All 15 women in the surgical group delivered healthy infants at term. In contrast, 48% of pregnancies complicated by untreated hyperparathyroidism ended in a miscarriage, which was directly related to the degree of hypercalcemia. 34 An association between maternal hypercalcemia and fetal polyhydramnios, fetal demise and neonatal hypocalcemia was shown in another retrospective case series. 35 Thus, maternal hypercalcemia should be ruled out in women with a history of unexplained fetal loss, polyhydramnios, previous neonatal hypocalcemia or severe hyperemesis. 36 In view of established medical and obstetrical complications of untreated maternal hypercalcemia and safety of parathyroidectomy during the second trimester, women diagnosed with primary hyperparathyroidism early in pregnancy should be carefully considered for surgery. Management of significant hypercalcemia diagnosed after 28 weeks of gestation should be individualized with regards to fetal maturity, growth, degree of hypercalcemia and the maternal obstetrical history. Frequent antenatal ultrasounds should be carried out to monitor fetal growth and other complications such as polyhydramnios. Once fetal maturity has been established, vaginal delivery or cesarean section should be considered to limit fetal exposure to maternal hypercalcemia. Recognizing the significant risk to the mother and unborn child, women with untreated hypercalcemia during pregnancy should be managed by a multidisciplinary team of experienced endocrinologists, obstetricians and, when appropriate, endocrine surgeons.
In conclusion, we report the safe and successful application of ultrasound-guided fine-needle aspiration of a suspected parathyroid lesion in a pregnant woman with primary hyperparathyroidism. A high level of PTH from the needle washout confirmed the preoperative localization of a parathyroid adenoma, which was pathologically confirmed in the surgical specimen. Our review of the literature did not identify any previous case of a pregnant woman with primary hyperparathyroidism, where preoperative localization of a parathyroid adenoma was accomplished by aspiration of a suspected lesion followed by successful minimally invasive parathyroidectomy during pregnancy. This paper highlights the value of preoperative neck ultrasound for localization of parathyroid adenomas followed by minimally invasive parathyroidectomy with the use of a rapid, intraoperative PTH assay in pregnant women with primary hyperparathyroidism.
